Reason for request



Clinical Benefit


The actual benefit of IMNOVID is substantial in the Marketing Authorisation indication.

Clinical Added Value


MNOVID, in combination with dexamethasone, provides a moderate improvement in actual benefit (IAB III) in terms of efficacy in the treatment of relapsed and refractory multiple myeloma in adult patients who have already received at least two prior treatment regimens with lenalidomide and bortezomib and who have demonstrated disease progression on the last therapy.